NovoCure Limited (NVCR) Stock Analysis

Q: What is the NVCR stock price target?

Take-profit $21.81 (+47.0% upside). Prior stop was $13.80.

Q: Is NVCR overvalued or undervalued?

NovoCure Limited trades at a P/E of N/A (forward -10.2). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about NVCR?

13 analysts cover NVCR with a consensus score of 4.1/5. Average price target: $25.

Recovery setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Medical Devices

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $14.77: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality.

$14.77+47.0% A.UpsideScore 5.4/10#17 of 40 Medical Devices

Stop $13.80Target $21.81(analyst − 13%)A.R:R 3.1:1

Analyst target$25.07+69.7%7 analysts

$21.81our TP

$14.77price

$25.07mean

$49

Passes 5/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (3.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-10.2

Mkt Cap$1.4B

EV/EBITDA-8.6

Profit Mgn-20.8%

ROE-38.9%

Rev Growth8.1%

Beta0.82

DividendNone

Rating analysts13

Quality Signals

Piotroski F6/9

Options Flow

P/C1.27bearish

IV99%elevated

Max Pain$4-72.9% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality3.415%0.51

Growth4.515%0.67

Momentum8.310%0.83

Sentiment7.710%0.77

Insider Activity3.410%0.34

Peer Rank2.910%0.29

Technical Setup2.15%0.11

Risk Profile3.95%0.20

Catalyst7.65%0.38

Overall (Σ contributions)5.45

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger

0.0

Support Resistance

0.7

Gap

3.0

52w Position

4.8

Extreme gap up (12.0%) - may pull back

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

1.2

Growth Rank

4.3

Value Rank

6.0

Unprofitable operations — net margin -20.8%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Rule Of 40

3.0

Moat

5.0

Piotroski F

6.7

Current Ratio

9.7

Gross Margin

10.0

Cash-burning: FCF -6% of revenueNo competitive moatRule of 40: 2 (fail)

GatesEARNINGS PROXIMITY 0d<=7dDeath cross (50MA < 200MA)Momentum 8.3>=5.5A.R:R 3.1 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

78 · Overbought

↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $10.13Resistance $15.20

Price Targets

$14

$22

A.Upside+47.7%

A.R:R3.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (3.4 < 4.0)

! EARNINGS_PROXIMITY:0d<=7d

Earnings

4/4 beats

Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is NVCR stock a buy right now?

Sell if holding. Engine safety override at $14.77: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 78. Prior stop was $13.80. Score 5.4/10, moderate confidence.

What is the NVCR stock price target?

Take-profit target: $21.81 (+47.0% upside). Prior stop was $13.80. Stop-loss: $13.80.

What are the risks of investing in NVCR?

Quality below floor (3.4 < 4.0).

Is NVCR overvalued or undervalued?

NovoCure Limited trades at a P/E of N/A (forward -10.2). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about NVCR?

13 analysts cover NVCR with a consensus score of 4.1/5. Average price target: $25.

What does NovoCure Limited do?NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating...

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.